Conference Presentation

SonoClear device data on tumor-margin imaging head to EANS in October

A pivotal multicenter study of SonoClear's acoustic coupling fluid, which carries FDA Breakthrough Device status, will be presented at a European neurosurgery congress ahead of a still-pending US clearance.

By AppliedXLJuly 13, 2026Trial NCT04734444

Executive Summary

SonoClear AS will publicly disclose pivotal data on its acoustic coupling fluid for the first time at a major European neurosurgery congress, after years of registry silence on the underlying study.
The presentation addresses a narrow but real limitation of intraoperative ultrasound in brain tumor surgery: image artifacts in the resection cavity that can obscure residual tumor, a problem the device is designed to solve.
The device already carries FDA Breakthrough Device status, positioning this data disclosure as supporting evidence for a submission already underway rather than an early feasibility signal.
No trial in the glioma-surgery field shares this device's modality or mechanism, so the presentation lands into a field with device, radiopharmaceutical, and small-molecule programs but no true comparator.
The underlying study ran years past its original schedule and sat in an ambiguous registry status before closing, a pattern that shapes how much weight the upcoming data should carry until seen.

The presentation

SonoClear AS said the abstract, titled "An Acoustic Coupling Fluid Improves Intraoperative Ultrasound Image Quality During Glioma Surgery: Results of a Pivotal Multicenter Study," was accepted for oral presentation at the European Association of Neurosurgical Societies' 2026 Annual Congress, running September 30 to October 4 in Hamburg, Germany. Francesco DiMeco, a neurosurgery professor at the University of Milan and director of neurological surgery at Istituto Nazionale Neurologico Carlo Besta, will deliver the talk on October 1. DiMeco said intraoperative ultrasound's main limitation is "the occurrence of resection cavity artifacts at the end of tumor removal," and that the presentation will share results from a multicenter study evaluating whether the coupling fluid overcomes those artifacts and improves image quality. Findings

What the device does

The SonoClear System is a sterile, biocompatible ultrasound coupling fluid engineered to match the acoustic properties of brain tissue, intended to eliminate the bright-signal artifacts that standard saline irrigation creates during tumor resection. Clearer visualization of the resection cavity is meant to help surgeons distinguish tumor margin from healthy tissue, which the company frames as a route to a more complete resection. The device has been granted Breakthrough Device status by the FDA and is not yet available for sale. Findings

The underlying trial

The pivotal study behind the presentation is registered as NCT04734444, an interventional device study in high-grade and low-grade glioma run across sites in Germany, Italy, and Slovakia, with a primary outcome measure of adverse events through 30 days post-procedure. The trial started enrolling in September 2021 and raised its enrollment target from 20 to 38 patients in April 2023, then to 37 in May 2023. Its status moved to "Unknown status" in May 2025 after roughly three years without a registry update, then to Completed in June 2025, with enrollment recorded at 45. The primary completion date moved three times, from December 2021 to March 2022, then October 2022, then January 2024. NCT04734444

Competitive field

No trial in the glioma or glioblastoma field shares this device's modality or mechanism. The closest indication-matched programs test different approaches entirely: NovoCure's Optune (a tumor-treating-fields device), GT Medical Technologies' GammaTile (a radiation-emitting implant), and Everfront Biotech's Cerebraca Wafer, alongside small-molecule programs such as Nuvation Bio's safusidenib and Servier's vorasidenib in glioma more broadly. None of these compete on the same axis, which is intraoperative visualization quality rather than tumor-cell killing, so the presentation lands into a field with active programs but no direct comparator for what SonoClear is actually testing.

What the data can establish

As a device study measuring adverse events and image-quality outcomes rather than a randomized efficacy trial against a validated survival endpoint, the presentation can establish whether the coupling fluid measurably reduces the imaging artifacts surgeons rely on to judge the extent of resection. That is the tolerability and performance signal the sponsor needs ahead of a US submission built on its Breakthrough Device designation, not a survival or recurrence result. NCT04734444+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.